Table 1 Baseline characteristics of study population
Characteristics | Clopidogrel plus aspirin | Aspirin alone | p |
|---|---|---|---|
(n = 159) | (n = 834) | ||
Age (years, mean ± SE) | 64.6 ± 1.0 | 68.3 ± 0.4 | 0.0005 |
Women | 32 (20.13%) | 329 (39.45%) | <0.0001 |
Medical history | |||
Cerebrovascular disease | 40 (25.16%) | 375 (44.96%) | <0.0001 |
Ischemic heart disease | 140 (88.05%) | 536 (64.27%) | <0.0001 |
Liver disease | 38 (23.9%) | 369 (44.24%) | <0.0001 |
Kidney disease | 57 (35.85%) | 378 (45.32%) | 0.0273 |
Hypertension | 107 (67.3%) | 495 (59.35%) | 0.0603 |
Diabetes mellitus | 122 (76.73%) | 606 (72.66%) | 0.2879 |
Hyperlipidemia | 147 (92.45%) | 668 (80.10%) | 0.0002 |
Current medication | |||
Insulin | 3 (1.89%) | 60 (7.19%) | 0.0119 |
Oral hypoglycemic drug | 25 (15.72%) | 106 (12.71%) | 0.3035 |
Lipid-lowering drug | 38 (23.9%) | 144 (17.27%) | 0.0476 |
Antihypertensive drug | 51 (32.08%) | 590 (70.74%) | <0.0001 |
ARB | 27 (16.98%) | 199 (23.86%) | 0.0579 |
ACEI | 4 (2.52%) | 49 (5.88%) | 0.0841 |
Beta-blocker | 7 (4.4%) | 53 (6.35%) | 0.3437 |
CCB | 39 (24.53%) | 524 (62.83%) | <0.0001 |
Thiazide diuretic | 9 (5.66%) | 127 (15.23%) | 0.0013 |
Other | 14 (8.81%) | 80 (9.59%) | 0.756 |
NSAID | 12 (7.55%) | 191 (22.9%) | <0.0001 |
Steroid | 4 (2.52%) | 82 (9.83%) | 0.0026 |
H2 blocker | 17 (10.69%) | 455 (54.56%) | <0.0001 |
Proton pump inhibitor | 19 (11.95%) | 151 (18.11%) | 0.059 |
Antiepileptic drug | 2 (1.26%) | 55 (6.59%) | 0.008 |
Immunosuppressive drug | 0 (0%) | 18 (2.16%) | 0.0616 |
Diuretic | 8 (5.03%) | 129 (15.47%) | 0.0005 |
Antiarrhythmic drug | 12 (7.55%) | 104 (12.47%) | 0.0765 |